Bortezomib, thalidomide, dexamethasone, and panobinostat for patients with relapsed multiple myeloma (MUK-six): a multicentre, open-label, phase 1/2 trial-Reference-Cited by-同舟云学术

Bortezomib, thalidomide, dexamethasone, and panobinostat for patients with relapsed multiple myeloma (MUK-six): a multicentre, open-label, phase 1/2 trial

Published:2016-12 Issue:12 Volume:3 Page:e572-e580
ISSN:2352-3026
Container-title:The Lancet Haematology
language:en
Short-container-title:The Lancet Haematology

Author:

Popat Rakesh,Brown Sarah R,Flanagan Louise,Hall Andrew,Gregory Walter,Kishore Bhuvan,Streetly Matthew,Oakervee Heather,Yong Kwee,Cook Gordon,Low Eric,Cavenagh Jamie

Publisher

Elsevier BV

Subject

Hematology

Reference19 articles.

1. Superiority of bortezomib, thalidomide, and dexamethasone (VTD) as induction pretransplantation therapy in multiple myeloma: a randomized phase 3 PETHEMA/GEM study;Rosinol;Blood,2012

2. Bortezomib-thalidomide-dexamethasone (VTD) is superior to bortezomib-cyclophosphamide-dexamethasone (VCD) as induction therapy prior to autologous stem cell transplantation in multiple myeloma;Cavo;Leukemia,2015

3. VTD combination therapy with bortezomib-thalidomide-dexamethasone is highly effective in advanced and refractory multiple myeloma;Pineda-Roman;Leukemia,2008

4. Panobinostat plus bortezomib and dexamethasone in previously treated multiple myeloma: outcomes by prior treatment;Richardson;Blood,2016

5. Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial;San-Miguel;Lancet Oncol,2014

Cited by 36 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Targeting the epigenome to reinvigorate T cells for cancer immunotherapy;Military Medical Research;2023-12-04

2. Histone deacetylase‐based dual targeted inhibition in multiple myeloma;Medicinal Research Reviews;2023-05-16

3. Epigenetic regulation in hematopoiesis and its implications in the targeted therapy of hematologic malignancies;Signal Transduction and Targeted Therapy;2023-02-17

4. Repetitive transcranial magnetic stimulation for chemotherapy-induced peripheral neuropathy in multiple myeloma: A pilot study;SAGE Open Medicine;2023-01

5. Treatment Options for Patients With Heavily Pretreated Relapsed and Refractory Multiple Myeloma;Clinical Lymphoma Myeloma and Leukemia;2022-07